Trial Profile
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Bremelanotide (Primary)
- Indications Decreased libido; Female sexual dysfunction
- Focus Therapeutic Use
- Acronyms HSDD; RECONNET
- Sponsors Palatin Technologies
- 01 Mar 2022 Results of this study and the extension study assessing pre-specified and sub-group analysis assessing efficacy of bremelanotide were published in the Journal of Women's Health.
- 27 Apr 2020 Results effect of bremelanotide on ambulatory blood pressure when administered for up to 16 consecutive days, presented at the 69th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
- 16 Oct 2019 According to a Palatin Technologies media release, data from RECONNECT trials will be presented by Sheryl Kingsberg at the 13th European Society of Gynecology Conference 2019. The conference and the data presentations are jointly sponsored by Palatin and AMAG Pharmaceuticals, Inc.